EyePoint公司
DE ˙ DB ˙ US30233G2093
€10.10 ↓ -0.30 (-2.88%)
2026-06-04
分享價格
SecurityDE:PV3B / EyePoint, Inc.
InstitutionDynamic Technology Lab Private Ltd
Latest Disclosed Ownership12,067 shares
Latest Disclosed Value $ 155,544
Dynamic Technology Lab Private Ltd ownership in PV3B / EyePoint, Inc.

On May 15, 2026 - Dynamic Technology Lab Private Ltd filed a 13F-HR form disclosing ownership of 12,067 shares of EyePoint, Inc. (DE:PV3B) valued at $120,730 USD as of March 31, 2026. The entity filed a previous 13F-HR on August 12, 2025 disclosing 0 shares of EyePoint, Inc.. The current value of the position is $121,877 USD.

Institutional Ownership: 13F and NPORT Filings

The Security and Class in the table below are shown exactly as filed by the investor. We do our best to track continuity of investments through acquisitions, and this will be reflected in the table as changes in names. In addition to descriptive data, performance of the investment is shown over time. To calculate quarterly performance, we first calculate cost basis of the shares purchased during the quarter, then use that to calculate gross profit. Quarterly return is Gross Profit / Starting Portfolio value.

Note that cost basis is calculated and stored in thousands, so small quarterly changes in shares frequently result in a cost basis of zero.

Upgrade to unlock premium data and export to Excel .

Disclosed Equity Positions (from 13F/NPORT Filings)
File
Date
Effective
Date
Form Security Class ID Avg Price
Paid (Est)
Reported
Shares
ΔShares ΔShares
(%)
Reported
Value
(x1000)
ΔValue
(%)
Alloc
(%)
ΔAlloc ΔAlloc (%) Cost Basis
(x1000)
Unrealized
Gain/Loss
(x1000)
2026-05-15 2026-03-31 13F EYEPOINT COM NEW 30233G209 12,067 12,067 156 0.0253
2025-08-12 2025-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 0 -73,310 -100.00 0 -100.00
2025-05-16 2025-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 73,310 41,132 127.83 397 65.42 0.0575
2025-02-13 2024-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 32,178 20,129 167.06 240 150.00 0.0386
2024-11-13 2024-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 12,049 -41,139 -77.35 96 0.0102
2024-08-15 2024-06-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 53,188 38,479 261.60 0 0.0523
2024-05-14 2024-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 14,709 14,709 0 0.0326
2024-02-09 2023-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 0 -38,587 -100.00 0 0.0000
2023-11-14 2023-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 38,587 38,587 0 0.0308
2023-02-14 2022-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 0 -12,926 -100.00 0 -100.00
2022-11-14 2022-09-30 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 12,926 12,926 102 0.0101
2022-05-16 2022-03-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 0 -32,523 -100.00 0 -100.00
2022-02-14 2021-12-31 13F EYEPOINT PHARMACEUTICALS COM NEW 30233G209 32,523 32,523 398 0.0441
Legend
Shares
The total number of shares held by the institution at the end of the reporting period (the effective date). This is provided in the filing.
Value
The total value of the shares as of the effective date. This is provided in the filing.
Avg. Share Price
The weighted average share price of the shares held by the institution. We use FIFO accounting to determine this price
Class
This is the security class as indicated by the filer. There are a variety of values for this field. Common values include "EC" = equity common, "EP" - equity preferred
Allocation (%)
The percent of the institution's portfolio that this position represents. This is provided in NPORT filings. For 13F filings, we calculate it.
Change in Allocation
The change in allocation from the prior reporting period. This is calculated as current allocation - prior allocation.
Change in Allocation (%)
The percent change in allocation from the prior reporting period. This is calculated as (current allocation - prior allocation) / prior allocation.
Cost Basis
The total cost of the shares held. This is calculated as reported shares * avg. share price
Unrealized Gain/Loss
This is the market value of the position as of the effective date minus the cost basis.